Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
51.65
-1.35 (-2.55%)
Sep 9, 2025, 4:08 PM HKT
-2.55%
Market Cap58.09B
Revenue (ttm)7.12B
Net Income (ttm)323.95M
Shares Outn/a
EPS (ttm)0.38
PE Ratio179.33
Forward PE42.03
Dividend0.32 (0.63%)
Ex-Dividend DateJun 12, 2025
Volume1,300,200
Average Volume2,781,397
Open52.45
Previous Close53.00
Day's Range51.00 - 53.25
52-Week Range22.30 - 60.60
Beta0.82
RSI51.45
Earnings DateAug 29, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.